Texas Roadhouse earnings missed by $0.05, revenue topped estimates
Investing.com -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported second-quarter earnings that missed analyst expectations, sending shares down 2% despite slightly exceeding revenue estimates.
The biopharmaceutical company posted an adjusted loss of $8.25 per share for the second quarter, falling short of analyst expectations for a loss of $7.62 per share. Revenue came in at $1.05 billion, marginally above the consensus estimate of $1.04 billion and up 2.1% from the same quarter last year. The company’s stock declined 2% following the earnings release, primarily due to the earnings miss.
Jazz updated its 2025 revenue guidance to a range of $4.15-$4.30 billion, representing 4% growth at the midpoint. The company also raised the lower end of its net income and earnings per share ranges, citing reductions in SG&A and R&D expenses and an improved effective tax rate.
"We continue to see significant opportunity across our diversified portfolio in sleep, epilepsy, and oncology, as evidenced by the strong performance this quarter from our sleep portfolio with robust continued growth from Xywav in both narcolepsy and IH," said Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals.
The company’s sleep medication Xywav was a bright spot, with net product sales increasing 13% YoY to $415.3 million. Jazz reported approximately 15,225 active Xywav patients at the end of the quarter, including about 4,625 idiopathic hypersomnia patients. Meanwhile, Epidiolex/Epidyolex sales grew 2% to $251.7 million, while Rylaze/Enrylaze and Zepzelca sales declined 7% and 8% respectively.
Jazz highlighted several upcoming catalysts, including top-line data from zanidatamab in Phase 3 trials expected in Q4 2025 and upcoming PDUFA dates for dordaviprone and Zepzelca. The company also completed its acquisition of Chimerix (NASDAQ:CMRX) in April, adding dordaviprone to its late-stage pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.